United Therapeutics Co. (NASDAQ:UTHR) has been assigned an average recommendation of “Buy” from the eleven analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $156.57.
Several research firms have recently issued reports on UTHR. Wedbush increased their price target on United Therapeutics from $247.00 to $255.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. BidaskClub upgraded shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 11th. Oppenheimer raised their target price on shares of United Therapeutics from $165.00 to $175.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. ValuEngine lowered shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 1st. Finally, JPMorgan Chase & Co. initiated coverage on shares of United Therapeutics in a research note on Monday, September 14th. They set an “overweight” rating on the stock.
Institutional investors have recently bought and sold shares of the business. Marshall Wace North America L.P. lifted its position in shares of United Therapeutics by 922.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 318,336 shares of the biotechnology company’s stock valued at $38,519,000 after acquiring an additional 287,192 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of United Therapeutics by 35.8% during the third quarter. First Trust Advisors LP now owns 847,262 shares of the biotechnology company’s stock valued at $85,573,000 after purchasing an additional 223,194 shares during the last quarter. Point72 Asset Management L.P. boosted its position in shares of United Therapeutics by 63.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 440,527 shares of the biotechnology company’s stock valued at $44,493,000 after purchasing an additional 171,218 shares during the period. AJO LP increased its stake in United Therapeutics by 66.2% in the 3rd quarter. AJO LP now owns 246,960 shares of the biotechnology company’s stock worth $24,942,000 after purchasing an additional 98,326 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its holdings in United Therapeutics by 213.1% during the 2nd quarter. Ensign Peak Advisors Inc now owns 141,805 shares of the biotechnology company’s stock worth $17,159,000 after buying an additional 96,521 shares during the period. Hedge funds and other institutional investors own 94.37% of the company’s stock.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported $3.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $1.43. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The business had revenue of $380.10 million during the quarter, compared to the consensus estimate of $357.95 million. During the same period in the previous year, the firm posted $3.83 earnings per share. The business’s revenue was down 5.3% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics will post 10.45 earnings per share for the current fiscal year.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.